Status checked on October 6, 2026 dailymed.nlm.nih.gov
Wegovy HD (semaglutide 7.2 mg): FDA approved March 19, 2026 for adults; who the label covers, STEP UP results, dysesthesia and other side effects, and dated prices.
Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.
Key facts
- Active ingredient
- Semaglutide: one ingredient, several brands
- Class
- GLP-1 receptor agonist
- Route
- Injection
- How often
- Weekly
- Manufacturer
- Novo Nordisk
- Approved for weight
- Yes
- First approved
- 2026
- Generic available
- No
- Controlled substance
- No
- Official label
- Prescribing information
Key takeaways
- Wegovy HD is a 7.2 mg once-weekly semaglutide pen, FDA approved on March 19, 2026 for weight reduction and maintenance in adults.[3]
- The label describes it as an option after at least 4 weeks on 2.4 mg when additional weight reduction is clinically indicated; it is not labeled for teens, MASH or heart-risk reduction.[1]
- In STEP UP, adults lost 18.8% of body weight on average at 72 weeks with 7.2 mg, vs 15.5% with 2.4 mg and 3.9% with placebo.[1]
- Dysesthesia (tingling or burning skin sensations) was reported by 22% on 7.2 mg vs 6% on 2.4 mg and 0.3% on placebo.[1]
- NovoCare Pharmacy self-pay was $399 a month for Wegovy HD, checked on 2026-10-06; the list price was $1,349.02 per package.[7]
In short: Wegovy HD is the higher-strength Wegovy pen: a once-weekly 7.2 mg dose of semaglutide, three times the standard 2.4 mg top dose. The FDA approved it on March 19, 2026 for weight reduction and long-term maintenance in adults, as an option for people who have taken 2.4 mg for at least 4 weeks and need more weight reduction. In its main trial, adults lost 18.8% of their weight on average over 72 weeks, compared with 15.5% on 2.4 mg and 3.9% on placebo (status checked on the FDA label on 2026-10-06).
This page explains what is different about Wegovy HD compared with regular Wegovy: who the label covers, how the step up works in general, what the STEP UP trials found, which side effects become more common at the higher dose (especially a skin-sensation side effect called dysesthesia), and what it costs. It is general information to prepare for a conversation with your clinician, not personal medical advice.
Wegovy HD at a glance
- 7.2 mgonce-weekly dose in a single-dose pen (0.75 mL)Wegovy prescribing information
- March 19, 2026FDA approval of the 7.2 mg weekly dose (NDA 215256/S-029)Drugs@FDA
- -18.8%average weight change at 72 weeks in Study 8 (STEP UP)Wegovy prescribing information
- $399self-pay per month at NovoCare PharmacyNovoCare Pharmacy
Checked on October 6, 2026
What Wegovy HD is
Wegovy HD is not a new medicine. It contains the same active ingredient as every Wegovy product, semaglutide, a GLP-1 receptor agonist that slows stomach emptying and acts on appetite centers in the brain. Our semaglutide page explains the mechanism in detail, and the GLP-1 medications guide covers the whole class. What changes is the amount: each Wegovy HD pen delivers 7.2 mg of semaglutide in 0.75 mL, compared with a maximum of 2.4 mg in the regular Wegovy pens.
According to the label, the average steady-state level of semaglutide in the blood was about 75 nmol/L with 2.4 mg weekly and about 230 nmol/L with 7.2 mg weekly, and exposure rose in proportion to the dose. Semaglutide has a half-life of about one week, so it stays in the body for about 5 to 7 weeks after the last dose of either strength.
FDA status: approved, with a narrower use than regular Wegovy
Drugs@FDA lists a supplement to the Wegovy application, NDA 215256/S-029, approved on March 19, 2026, as a “new dosing regimen”. The FDA approval letter says it “provides for the addition of a new Wegovy injection 7.2 mg subcutaneous weekly dose for weight reduction and maintenance long term.” Novo Nordisk reported in its first-half 2026 report (filed with the SEC on August 4, 2026) that Wegovy HD launched in the U.S. in April 2026, and that the 7.2 mg dose was also approved in the UK and the EU.
The narrower part matters. In the current label, the 7.2 mg dose appears only under weight reduction in adults. For heart protection (cardiovascular risk reduction), the label’s maintenance doses remain 2.4 mg or 1.7 mg; for teens 12 and older, 2.4 mg or 1.7 mg; and for the liver condition MASH, 2.4 mg. The label states that the safety of Wegovy 7.2 mg has not been established in children or in people with MASH. The 7.2 mg strength exists only as an injection: Wegovy tablets top out at 25 mg a day and are a separate product, covered on our Wegovy pill page.
Who it is labeled for
Wegovy as a whole is labeled, with a reduced-calorie diet and more physical activity, for adults with obesity, or with overweight plus at least one weight-related condition. Within that, the label describes the 7.2 mg dose as an option for adults who have tolerated the 2.4 mg dose for at least 4 weeks when “additional weight reduction is clinically indicated”, with the choice of maintenance dose based on treatment response and tolerability. The STEP UP trials enrolled adults with a BMI of 30 or more. NIDDK describes weight-management medicines in general as considered for adults with a BMI of 30 or more, or 27 or more with a weight-related condition. Whether any dose fits a particular person is a decision for that person and their clinician; our BMI calculator shows where you stand but is not a diagnosis.
How the step up works, in general
Everyone starts Wegovy the same way: a low weekly dose, increased every 4 weeks over about 16 weeks to reach the standard maintenance dose. Wegovy HD is a further, optional step after that. Like other Wegovy pens, it is injected under the skin of the stomach, thigh or upper arm once a week, on the same day each week, with or without food. Novo Nordisk provides separate Instructions for Use for the Wegovy HD pen, and the Medication Guide says to get new training whenever you switch to a different Wegovy product. Your prescriber decides whether and when to move up, and what to do about missed doses or side effects; never change the dose on your own.
Where Wegovy HD fits in the Wegovy schedule (general, from the label)
- Start lowTreatment begins at the lowest weekly dose to let the stomach adjust.
- Step up every 4 weeksDoses rise every 4 weeks through the escalation period (weeks 1 to 16).
- Standard maintenanceFrom week 17, 1.7 mg or 2.4 mg weekly (2.4 mg recommended for weight).
- At least 4 weeks on 2.4 mgThe label sets this as the point from which a higher dose may be considered.
- Optional 7.2 mg (Wegovy HD)Only if more weight reduction is clinically indicated and the prescriber agrees.
What the STEP UP trials showed
Two 72-week, double-blind, randomized trials compared 7.2 mg, 2.4 mg and placebo, each with a lifestyle program. Study 8 (STEP UP, NCT05646706) enrolled 1,407 adults with a BMI of 30 or more and no diabetes (average weight 113 kg, average BMI 39.9, 74% women), randomized 5:1:1. Study 9 (STEP UP T2D, NCT05649137) enrolled 512 adults with obesity and type 2 diabetes, randomized 3:1:1.
| Item | Wegovy HD 7.2 mg | Wegovy 2.4 mg | Placebo |
|---|---|---|---|
| Study 8, obesity without diabetes | 18.8% | 15.5% | 3.9% |
| Study 9, obesity with type 2 diabetes | 13.2% | 10.4% | 3.8% |
Intention-to-treat estimates from the label. In Study 8, 7.2 mg vs 2.4 mg was -3.3 percentage points; 7.2 mg vs placebo -14.9 points.
Source: Wegovy prescribing information, Table 12 (Studies 8 and 9) (checked on October 6, 2026)
In Study 8, the extra benefit of 7.2 mg over 2.4 mg was 3.3 percentage points of body weight on average. The bigger difference shows up at the higher milestones: 45.5% of people on 7.2 mg lost 20% or more of their weight, compared with 32.3% on 2.4 mg and 2.8% on placebo. Waist size fell by 17.5 cm on 7.2 mg, 14.2 cm on 2.4 mg and 5.6 cm on placebo, and systolic blood pressure by 10.1, 8.5 and 4.8 mmHg. The peer-reviewed report in The Lancet Diabetes and Endocrinology (2025) gave -18.7% with 7.2 mg, -15.6% with 2.4 mg and -3.9% with placebo, using a slightly different statistical approach.
| Item | Wegovy HD 7.2 mg | Wegovy 2.4 mg | Placebo |
|---|---|---|---|
| 5% or more | 88.7% | 86.6% | 38.3% |
| 10% or more | 79.8% | 72% | 20.3% |
| 15% or more | 63.8% | 52.3% | 7.5% |
| 20% or more | 45.5% | 32.3% | 2.8% |
1,407 adults with a BMI of 30 or more and no diabetes. The 2.4 mg comparisons were informative only (not part of the formal testing hierarchy).
Source: Wegovy prescribing information, Table 12 (checked on October 6, 2026)
In Study 9 (adults with type 2 diabetes), average weight change was -13.2% with 7.2 mg, -10.4% with 2.4 mg and -3.8% with placebo, and 20.6% of people on 7.2 mg lost 20% or more. HbA1c (a three-month blood sugar measure) fell 1.7 points with 7.2 mg and 0.2 with placebo from an average of about 8%. As in all weight trials, people with diabetes lost less on average, and individual results varied widely.
What the trials did not test: STEP UP did not include a cardiovascular outcomes study at 7.2 mg (the heart-protection evidence for Wegovy, from the SELECT trial, used 2.4 mg), and it did not test what happens when someone stops 7.2 mg. Evidence from 2.4 mg, summarized on our life after a GLP-1 page, shows that most people regain much of the weight after stopping.
Side effects: what changes at the higher dose
The label has a separate side-effect table for 7.2 mg, built from Studies 8 and 9 (1,311 people on 7.2 mg, 304 on 2.4 mg, 303 on placebo). It lists reactions seen in at least 2% of people on 7.2 mg and more often than with both 2.4 mg and placebo. Digestive side effects were the most common, as with every GLP-1 medicine, and most appear during dose increases.
| Item | 7.2 mg | 2.4 mg | Placebo |
|---|---|---|---|
| Nausea | 39% | 35% | 13% |
| Vomiting | 22% | 16% | 6% |
| Dysesthesia (altered skin sensation) | 22% | 6% | 0% |
| Constipation | 20% | 19% | 8% |
| Abdominal pain | 12% | 9% | 7% |
| Fatigue | 11% | 9% | 5% |
| Headache | 9% | 8% | 7% |
| Dizziness | 6% | 5% | 1% |
| Hair loss | 6% | 3% | 1% |
| Flatulence | 4% | 2% | 2% |
Reactions in 2% or more of people on 7.2 mg and more often than on 2.4 mg and placebo. Placebo dysesthesia rounded to 0 in the table (0.3% in the text).
Source: Wegovy prescribing information, Table 4 (checked on October 6, 2026)
Dysesthesia is the side effect that stands out. It means unusual skin sensations: tingling, burning, pins and needles, skin that feels sensitive or painful to touch. The label reports it in 22% of people on 7.2 mg, 6% on 2.4 mg and 0.3% on placebo, and says it increased with the dose and blood levels. Among the 288 people on 7.2 mg who had it, 2% stopped the medicine, 8% paused it and 23% had their dose reduced; most of those recovered, and events resolved faster when an action was taken. Eighteen percent did not report recovery during the trial, mostly people whose dose was left unchanged. Of 38 people who went back up to 7.2 mg after recovering, 17 (45%) had it again. Tell your prescriber about any new skin sensations.
Hair loss was reported in 5.8% on 7.2 mg (8.4% of women, 0.2% of men), 3.3% on 2.4 mg and 1.0% on placebo; the label links hair loss to weight reduction. Stopping because of side effects was similar for the two doses: 5% on 7.2 mg, 5% on 2.4 mg and 2% on placebo, mostly for digestive reasons (3%, 3% and 0.3%). Antibodies to semaglutide developed in 15.4% of people on 7.2 mg and 11.2% on 2.4 mg; the label says the clinical effect of antibodies that cross-react with natural GLP-1 is unknown. For a deeper look at managing digestive side effects, see Wegovy side effects and our GLP-1 side effects guide.
Serious risks and the boxed warning
Wegovy HD shares the full Wegovy label, including its boxed warning: semaglutide caused thyroid C-cell tumors in rodents, and it is unknown whether it causes these tumors, including medullary thyroid carcinoma (MTC), in humans. It must not be used by anyone with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or by anyone with a prior serious allergic reaction to semaglutide or the product’s ingredients. The label’s warnings also cover acute pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, kidney injury from dehydration, severe stomach and bowel reactions, serious allergic reactions, diabetic eye complications in people with type 2 diabetes, a faster resting heart rate, and the risk of inhaling stomach contents during anesthesia or deep sedation. It is not recommended for people with severe gastroparesis.
Interactions, pregnancy and other cautions
Semaglutide slows stomach emptying, which can change how other oral medicines are absorbed; the label suggests closer monitoring for medicines with a narrow safety margin, and notes that semaglutide tablets increased levothyroxine levels by 33% in one study. With insulin or sulfonylureas, the risk of low blood sugar rises and those doses may need lowering. Wegovy should not be combined with other semaglutide products or other GLP-1 receptor agonists.
For pregnancy, the label says weight loss offers no benefit and may cause fetal harm, that Wegovy used for weight should be stopped when a pregnancy is recognized, and that it should be stopped at least 2 months before a planned pregnancy because of its long half-life. There is a pregnancy exposure registry (1-877-390-2760). Anyone pregnant, planning a pregnancy or breastfeeding should talk with their clinician before starting or continuing it.
Cost, insurance and savings
Prices checked on 2026-10-06 on Novo Nordisk’s NovoCare pages: the list price is $1,349.02 per package, the same for the Wegovy pen, the Wegovy HD pen and the pill. Self-pay through NovoCare Pharmacy is $399 a month for Wegovy HD (one box of 4 pens), compared with $349 a month for the regular pen strengths. People with commercial insurance that covers Wegovy may pay as little as $25 a month with the savings offer (maximum savings $100 a month; government beneficiaries excluded). Novo Nordisk said in its August 2026 report that it will lower the list price of Wegovy injection 2.4 mg and 7.2 mg to $675 from January 1, 2027. Insurance coverage of the higher dose depends on the plan; see our Wegovy cost page, the GLP-1 coverage guide and the GLP-1 cost comparison tool.
Compounded “high-dose semaglutide”
Wegovy HD is the only FDA-approved 7.2 mg semaglutide product. Compounded semaglutide is not FDA approved, and the FDA has received adverse-event reports, some requiring hospitalization, linked to dosing errors and to compounded doses beyond what the FDA-approved label describes. Buy only with a prescription from a state-licensed pharmacy. More in compounded GLP-1s.
Alternatives and comparisons
For people who have not reached their goal on 2.4 mg, other FDA-approved options include Zepbound (tirzepatide, a weekly injection that acts on two hormone receptors); see Wegovy vs Zepbound for the head-to-head trial. For some people, surgery is part of the conversation; our GLP-1 vs bariatric surgery page compares the two paths. Newer drugs in testing are listed on our emerging medications page. At any dose, protein and strength training help protect muscle; the protein calculator gives a daily range to discuss with your care team, and the medications hub lists every option with its status badge.
FDA status and approved uses
| Indication | Labeled population | For weight | Approved | Source |
|---|---|---|---|---|
| Reduce excess body weight and maintain weight reduction long term with the 7.2 mg once-weekly dosage (with reduced-calorie diet and increased physical activity) | Adults who have tolerated 2.4 mg for at least 4 weeks when additional weight reduction is clinically indicated (adults with obesity, or overweight with at least one weight-related comorbid condition) | Yes | March 19, 2026 | Source |
From the FDA label. Who a medicine is labeled for is not the same as whether it fits you; only a clinician can decide that.
How it is taken (in general)
Once weekly under the skin of the stomach, thigh or upper arm, same day each week, with or without meals. The label describes the usual 16-week escalation to a maintenance dose; for adults who have tolerated 2.4 mg for at least 4 weeks and need additional weight reduction, the dose may be increased to 7.2 mg (Wegovy HD single-dose pen). New training is advised when switching pens. Follow your prescriber; never change the dose on your own.
This is what the label describes in general, never a personal dose or schedule. Follow your prescriber.
What studies showed
| Trial | Population | Duration | Outcome as reported |
|---|---|---|---|
| STEP UP (Study 8) NCT05646706 | 1,407 adults with BMI 30+ without diabetes, randomized 5:1:1 to 7.2 mg, 2.4 mg or placebo | 72 weeks | Weight change -18.8% (7.2 mg) vs -15.5% (2.4 mg) vs -3.9% (placebo); 20% or more weight loss in 45.5% vs 32.3% vs 2.8%.[1] |
| STEP UP T2D (Study 9) NCT05649137 | 512 adults with obesity and type 2 diabetes (HbA1c 7-10%), randomized 3:1:1 | 72 weeks | Weight change -13.2% (7.2 mg) vs -10.4% (2.4 mg) vs -3.8% (placebo); HbA1c -1.7 vs -0.2 points (7.2 mg vs placebo).[1] |
Average results from trials; individual results vary. Results from different trials cannot be compared directly.
Side effects
| Common side effect | How often (label) |
|---|---|
| Nausea | 39% (7.2 mg) vs 35% (2.4 mg) vs 13% placebo |
| Vomiting | 22% vs 16% vs 6% |
| Dysesthesia (altered skin sensation) | 22% vs 6% vs 0.3% |
| Constipation | 20% vs 19% vs 8% |
| Abdominal pain | 12% vs 9% vs 7% |
| Fatigue | 11% vs 9% vs 5% |
| Hair loss | 6% vs 3% vs 1% (5.8% overall; 8.4% of women) |
Serious risks
- Thyroid C-cell tumors (boxed warning, seen in rodents)
- Acute pancreatitis
- Acute gallbladder disease
- Hypoglycemia, especially with insulin or a sulfonylurea
- Acute kidney injury from fluid loss
- Severe gastrointestinal adverse reactions
- Hypersensitivity reactions (anaphylaxis, angioedema)
- Diabetic retinopathy complications in people with type 2 diabetes
- Heart rate increase
- Pulmonary aspiration during general anesthesia or deep sedation
Warnings and who should not use it
Boxed warning
Risk of thyroid C-cell tumors: in rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Wegovy is contraindicated in patients with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled on the risk and symptoms of thyroid tumors.
Who should not use it (per the label)
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to semaglutide or any of the excipients
Interactions, pregnancy and breastfeeding
| Drug or class | What the label says |
|---|---|
| Other semaglutide products or GLP-1 receptor agonists | Not to be used together. |
| Insulin or insulin secretagogues (such as sulfonylureas) | Higher risk of low blood sugar; the prescriber may lower those doses. |
| Oral medications, especially narrow therapeutic index drugs | Delayed stomach emptying may change absorption; closer monitoring suggested (levothyroxine exposure rose 33% with semaglutide tablets). |
Pregnancy and breastfeeding
Weight loss offers no benefit to a pregnant patient and may cause fetal harm; discontinue Wegovy used for weight when pregnancy is recognized, and at least 2 months before a planned pregnancy because of the long half-life. Pregnancy registry: 1-877-390-2760. No data on injected semaglutide in human milk; discuss breastfeeding with the prescriber.
Cost, insurance and savings
| Price | Amount | Basis | Checked on |
|---|---|---|---|
| List price | 1,349.02 USD | per package (Wegovy HD pen; same as pen and pill) | October 6, 2026 |
| Self-pay / cash | 399 USD | per month (1 box of 4 pens), Wegovy HD 7.2 mg, NovoCare Pharmacy | October 6, 2026 |
| With savings program | 25 USD | per month with commercial coverage (max savings $100 a month; government beneficiaries excluded) | October 6, 2026 |
| List price | 675 USD | announced list price from 2027-01-01 (injection 2.4 mg and 7.2 mg) | October 6, 2026 |
Prices change often and depend on pharmacy, plan and location. Insurance can change what you pay. Every price shows the date we checked it.
Savings programs
- Wegovy Savings Offer: Commercial insurance that covers Wegovy; government beneficiaries excluded (checked October 6, 2026)
- NovoCare Pharmacy self-pay: Valid prescription; $399 a month for Wegovy HD (checked October 6, 2026)
Full price guide: Wegovy Cost, Coupons and Savings Programs (prices checked monthly)
Stopping and keeping results
Trials show that weight often returns after these medicines are stopped. Plan any change with your prescriber. Stopping a GLP-1: what trials show and how people keep results
Compounded and counterfeit versions
Compounded semaglutide and tirzepatide are not FDA approved: the FDA does not review them for safety, quality or effectiveness. Counterfeit pens and "research peptides" sold online have caused harm. Buy only from a licensed pharmacy with a prescription.
Same active ingredient
FDA approved for another usePrescriptionInjectionOzempic (semaglutide): approved uses and how it differs from WegovySemaglutide: one ingredient, several brands · Injection · Weekly
FDA approved for another usePrescriptionInjectionOzempic Side Effects: what the label lists and when to get helpSemaglutide: one ingredient, several brands
FDA approved for another useOff-label use discussedPrescriptionPillRybelsus (oral semaglutide): a diabetes pill, not a weight-loss approvalSemaglutide: one ingredient, several brands · Pill (tablet) · Daily
FDA approved for weight managementPrescriptionInjectionWegovy (semaglutide): uses, side effects, cost and FDA statusSemaglutide: one ingredient, several brands · Injection · Weekly
FDA approved for weight managementPrescriptionPillWegovy Pill (oral semaglutide): status, how it is taken, how it comparesSemaglutide: one ingredient, several brands · Pill (tablet) · Daily
FDA approved for weight managementPrescriptionInjectionWegovy Side Effects: common, serious and long-termSemaglutide: one ingredient, several brandsSame class
FDA approved for weight managementPrescriptionPillFoundayo (orforglipron): status, uses and what is confirmedOrforglipron: the small-molecule GLP-1 pill and its current status · Pill (tablet) · Daily
FDA approved for weight managementPrescriptionInjectionLiraglutide: the daily GLP-1 (Saxenda, Victoza) and genericsInjection · Daily
FDA approved for weight managementPrescriptionPillOrforglipron: the small-molecule GLP-1 pill and its current statusPill (tablet) · Daily
FDA approved for weight managementPrescriptionInjectionSaxenda (liraglutide 3 mg): uses, side effects and costLiraglutide: the daily GLP-1 (Saxenda, Victoza) and generics · Injection · Daily
FDA approved for weight managementPrescriptionInjectionSemaglutide: one ingredient, several brandsInjection · Daily, WeeklyNon-drug approaches
FDA approved for weight managementPrescriptionInjectionWegovy (semaglutide): uses, side effects, cost and FDA statusSemaglutide: one ingredient, several brands · Injection · Weekly
FDA approved for weight managementPrescriptionInjectionZepbound (tirzepatide): uses, side effects, cost and FDA statusTirzepatide: how the dual GIP/GLP-1 drug works (Zepbound, Mounjaro) · Injection · WeeklyFDA approved for weight managementPrescriptionPillFoundayo (orforglipron): status, uses and what is confirmedOrforglipron: the small-molecule GLP-1 pill and its current status · Pill (tablet) · Daily
How to Lose Weight: every proven approach in one placeHow to lose weight: the calorie deficit, food, activity, sleep and habits with the best evidence,…Research mentioning it
Related guides
GLP-1 Side Effects: common, serious and how they are managedGLP-1 side effects from the FDA labels: common digestive effects by brand, serious risks, the thyroid…
Stopping a GLP-1: regain, what trials show and keeping resultsWhat happens when you stop a GLP-1: STEP 1 extension, STEP 4, SURMOUNT-4 and BMJ meta-analysis…Tools for this topic
Questions to ask your doctor or pharmacist
- Based on my results on 2.4 mg, would the higher dose be expected to add meaningful benefit for me?
- How will we watch for dysesthesia, hair loss and digestive side effects, and what is the plan if they happen?
- Does my insurance cover Wegovy HD, or only the regular strengths?
- Should any of my other medicines, especially diabetes or thyroid medicines, be adjusted?
- How do we protect muscle and plan for the long term at this dose?
Frequently asked questions
Is Wegovy HD FDA approved?
Yes. The FDA approved the 7.2 mg weekly dose of Wegovy on March 19, 2026 (NDA 215256/S-029) for weight reduction and long-term maintenance in adults. Novo Nordisk reported a U.S. launch in April 2026.
How is Wegovy HD different from regular Wegovy?
Same medicine (semaglutide), higher dose: 7.2 mg per weekly injection instead of up to 2.4 mg. It is used only for weight in adults, after at least 4 weeks on 2.4 mg, and has its own single-dose pen and instructions.
How much more weight do people lose on 7.2 mg?
In STEP UP, the average was 18.8% with 7.2 mg vs 15.5% with 2.4 mg at 72 weeks, a 3.3-point difference. More people reached 20% loss (45.5% vs 32.3%). In adults with type 2 diabetes the averages were 13.2% vs 10.4%.
What is dysesthesia?
Unusual skin sensations such as tingling, burning, pins and needles or sensitivity to touch. It affected 22% of people on 7.2 mg in the trials. Most cases resolved, often after a pause or dose reduction; tell your prescriber if it happens.
Can I start directly on Wegovy HD?
No. The label describes the usual gradual escalation first, then at least 4 weeks on 2.4 mg before 7.2 mg may be considered. Your prescriber decides.
Can teenagers use Wegovy HD?
The label says the safety of Wegovy 7.2 mg has not been established in pediatric patients; for teens 12 and older the labeled maintenance doses are 2.4 mg or 1.7 mg.
Does Wegovy HD cost more?
The list price is the same ($1,349.02 per package), but NovoCare Pharmacy self-pay is $399 a month for HD vs $349 for the regular pens (checked on 2026-10-06). Insurance coverage depends on the plan.
Is there a Wegovy HD pill?
No. The 7.2 mg dose is only an injection. Wegovy tablets are a separate daily product with strengths up to 25 mg.
Is compounded high-dose semaglutide the same?
No. Compounded semaglutide is not FDA approved, and the FDA has received adverse-event reports linked to dosing errors and doses beyond the approved label. Wegovy HD is the only FDA-approved 7.2 mg product.
Official sources
References
- WEGOVY (semaglutide) injection and tablets: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- Drugs@FDA: Wegovy, NDA 215256, approval history. U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
- NDA 215256/S-029 and NDA 218316/S-005 approval letter (Wegovy injection 7.2 mg weekly dose). U.S. Food and Drug Administration, 2026. (accessed October 7, 2026) Government page
- Wharton S, Freitas P, Hjelmesaeth J, et al.. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes and Endocrinology, 2025. doi:10.1016/S2213-8587(25)00226-8 · PMID 40961952 · NCT05646706 (accessed October 6, 2026) Randomized trial
- Lingvay I, Bergenheim SJ, Buse JB, et al.. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. The Lancet Diabetes and Endocrinology, 2025. doi:10.1016/S2213-8587(25)00225-6 · PMID 40961953 · NCT05649137 (accessed October 6, 2026) Randomized trial
- Wegovy cost, coverage and savings resources. Novo Nordisk (NovoCare). (accessed October 6, 2026) Other
- Wegovy at NovoCare Pharmacy: self-pay prices. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Novo Nordisk financial report January-June 2026 (Form 6-K): REIMAGINE 4, AMAZE program, Wegovy HD. Novo Nordisk A/S, via U.S. Securities and Exchange Commission, 2026. (accessed October 6, 2026) Other
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, 2026. (accessed October 7, 2026) Government page
- Prescription Medications to Treat Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). (accessed October 7, 2026) Government page
Facts checked on October 6, 2026
Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.